1. Field of the Invention
This invention relates generally to an apparatus for delivering an electrical signal to a patient's body using an implantable medical device (IMD) system and, more particularly, an electrode comprising fibrous components for improved electrical contact with a targeted portion of the patient's body for delivering a stimulation signal from an IMD.
2. Description of the Related Art
Many advancements have been made in treating diseases such as epilepsy. Therapies using electrical signals for treating these diseases have been found to be effective. IMDs have been effectively used to deliver therapeutic stimulation to various portions of the human body (e.g., the vagus nerve) for treating these diseases. As used herein, “stimulation” or “stimulation signal” refers to the application of an electrical, mechanical, magnetic, electro-magnetic, photonic, audio and/or chemical signal to a target tissue in the patient's body. The signal is an exogenous signal that is distinct from the endogenous electrical, mechanical, and chemical activity (e.g., afferent and/or efferent electrical action potentials) generated by the patient's body and environment. In other words, the stimulation signal (whether electrical, mechanical, magnetic, electro-magnetic, photonic, audio, or chemical in nature) applied to the tissue in the present invention is a signal applied from an artificial source, e.g., a neurostimulator.
A “therapeutic signal” refers to a stimulation signal delivered to a patient's body with the intent of treating a disorder by providing a modulating effect to the target tissue, e.g., a neural tissue. The effect of a stimulation signal on electrical, chemical and/or mechanical activity in the target tissue is termed “modulation”; however, for simplicity, the terms “stimulating” and “modulating”, and variants thereof, are sometimes used interchangeably herein. In general, however, the delivery of an exogenous signal itself refers to “stimulation” of the target tissue, while the effects of that signal, if any, on the electrical, chemical and/or mechanical activity of the target tissue are properly referred to as “modulation.” The modulating effect of the stimulation signal upon the target tissue may be excitatory or inhibitory, and may potentiate acute and/or long-term changes in electrical, chemical and/or mechanical activity. For example, the “modulating” effect of the stimulation signal to a target neural tissue may comprise one more of the following effects: (a) initiation of an action potential (afferent and/or efferent action potentials); (b) inhibition or blocking of the conduction of action potentials, whether endogenously or exogenously induced, including hyperpolarizing and/or collision blocking, (c) affecting changes in neurotransmitter/neuromodulator release or uptake, and (d) changes in neuro-plasticity or neurogenesis of brain tissue.
Electrical neurostimulation may be provided by implanting an electrical device underneath the patient's skin and delivering an electrical signal to a nerve, such as a cranial nerve. In one embodiment, the electrical neurostimulation involves sensing or detecting a body parameter, with the electrical signal being delivered in response to the sensed body parameter. This type of stimulation is generally referred to as “active,” “feedback,” or “triggered” stimulation. In another embodiment, the system may operate without sensing or detecting a body parameter once the patient has been diagnosed with a medical condition that may be treated by neurostimulation. In this case, the system may apply a series of electrical pulses to the nerve (e.g., a cranial nerve such as a vagus nerve) periodically, intermittently, or continuously throughout the day, or over another predetermined time interval. This type of stimulation is generally referred to as “passive,” “non-feedback,” or “prophylactic,” stimulation. The electrical signal may be applied by an IMD that is implanted within the patient's body. In another alternative embodiment, the signal may be generated by an external pulse generator outside the patient's body, coupled by an RF or wireless link to an implanted electrode.
Generally, neurostimulation signals that perform neuromodulation are delivered by the IMD via one or more leads. The leads generally terminate at their distal ends in one or more electrodes, and the electrodes, in turn, are electrically coupled to tissue in the patient's body. For example, a number of electrodes may be attached to various points of a nerve or other tissue inside a human body for delivery of a neurostimulation signal.
Turning now to
State-of-the-art electrode assembly 100 may only provide adequate stimulation (i.e., may only modulate electrical activity of) individual nerve fibers (axons) that are in close proximity to the outside surface of the nerve trunk. Some patients may not respond to neurostimulation therapy due to the failure of electrical signals delivered to the outer portions of the nerve trunk 120 to penetrate to a sufficient depth within the nerve trunk to recruit nerve axons that are relevant to the patient's condition. This factor may result in a reduced efficacy of the therapy or in some cases a complete failure of the patient to respond to the therapy.
Another problem associated with the state-of-the-art electrode assembly 100 is that, as a result of the attenuation described above, a signal with larger power than otherwise would have been required, is needed to achieve desired efficacy. Physicians may be compelled to increase the dosage, i.e., frequency, power, pulse width, etc., of stimulation signals to achieve desired efficacy. This excessive usage of power may result in reduced battery life because of the portion of the electrical signal that is non-therapeutic or sub-optimal in achieving therapeutic efficacy.
The present invention is directed to overcoming, or at least reducing, the effects of one or more of the problems set forth above.
In one aspect, an apparatus is provided for employing an electrode for delivering an electrical signal to a target nerve of a tissue of a patient's body, wherein the nerve comprises an outer surface and an inner portion. The electrode includes an inner surface to contact to the outer surface of the target nerve. The electrode also includes a plurality of fiber elements comprising a proximal end and a distal end. The fiber elements are coupled at the proximal end to the inner surface of the electrode.
In another aspect, an apparatus is provided for employing an electrode for delivering an electrical signal to a target nerve of a tissue of a patient's body, wherein the nerve comprises an outer surface and an inner portion. The electrode includes a first surface to electrically couple to the cranial nerve. The electrode also includes a plurality of fibers having a proximal end and a distal end. Each of the fibers is coupled to the first surface at the proximal end. The fibers are conductive and adapted to migrate beneath the outer surface of the cranial nerve to deliver an electrical signal to the inner portion of the cranial nerve.
In yet another aspect of the present invention, an implantable medical device system is provided for delivering an electrical signal to a portion of a target tissue of a patient's body. The tissue comprises an outer surface and an interior portion. The IMD system includes an IMD for generating an electrical signal. The system also includes an electrode that is operatively coupled to the IMD. The electrode is provided for delivering the electrical signal to the target tissue of a patient's body. The electrode includes a first surface to electrically couple to an outer surface of the target tissue. The electrode also includes a plurality of longitudinal elements coupled to the first surface. The plurality of longitudinal elements are adapted to electrically couple to at least one of the outer surface and the interior portion of the target tissue.
The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Illustrative embodiments of the invention are described herein. In the interest of clarity, not all features of an actual implementation are described in this specification. In the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the design-specific goals, which will vary from one implementation to another. It will be appreciated that such a development effort, while possibly complex and time-consuming, would nevertheless be a routine undertaking for persons of ordinary skill in the art having the benefit of this disclosure.
This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “includes” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to.” Also, the term “couple” or “couples” is intended to mean either a direct or an indirect electrical connection. “Direct contact,” “direct attachment,” or providing a “direct coupling” indicates that a surface of a first element contacts the surface of a second element with no substantial attenuating medium there between. The presence of substances, such as bodily fluids, that do not substantially attenuate electrical connections does not vitiate direct contact. The word “or” is used in the inclusive sense (i.e., “and/or”) unless a specific use to the contrary is explicitly stated.
The term “electrode” or “electrodes” described herein may refer to one or more stimulation electrodes (i.e., electrodes for delivering an electrical signal generated by an IMD to a tissue), sensing electrodes (i.e., electrodes for sensing a physiological indication of a patient's body), and/or electrodes that are capable of delivering a stimulation signal, as well as performing a sensing function.
Cranial nerve stimulation has been proposed to treat a number of disorders pertaining to or mediated by one or more structures of the nervous system of the body, including epilepsy and other movement disorders, depression, anxiety disorders and other neuropsychiatric disorders, dementia, traumatic brain injury, head trauma, coma, migraine headache, obesity, eating disorders, sleep disorders, cardiac disorders (such as congestive heart failure and atrial fibrillation), hypertension, endocrine disorders (such as diabetes and hypoglycemia) and pain, among others. See, e.g., U.S. Pats. Nos. 4,867,164; 5,299,569; 5,269,303; 5,571,150; 5,215,086; 5,188,104; 5,263,480; 6,587,719; 6,609,025; 5,335,657; 6,622,041; 5,916,239; 5,707,400; 5,231,988; and 5,330,515. Despite the numerous disorders for which cranial nerve stimulation has been proposed or suggested as a treatment option, the fact that detailed neural pathways for many (if not all) cranial nerves remain relatively unknown, makes predictions of efficacy for any given disorder difficult or impossible. Moreover, even if such pathways were known, the precise stimulation parameters that would modulate particular pathways relevant to a particular disorder generally cannot be predicted.
Despite the difficulties of predicting efficacy for particular disorders, the use of vagus nerve stimulation as a therapy for treating epilepsy and/or depression is an established therapy option. Electrodes may be used in a system to deliver therapeutic electrical signals from an IMD to a target portion of a patient's body (e.g., a vagus nerve) for treating these and other diseases. Embodiments of the present invention provide for a “fibrous electrode,” which refers to an electrode upon which one or more “fibers” may be coupled. Some embodiments of the present invention provide for a “longitudinal element” coupled to a surface of an electrode. As used herein, a longitudinal element refers to an element whose longest dimension substantially exceeds other dimensions, e.g., length, width, cross-section, etc. Thus, a longitudinal element may comprise a “fiber” as previously disclosed. An example of a fiber may include, but is not limited to, a flexible material that is in mechanical and electrical communication with the electrode. These flexible materials may be formed from carbon nanotubes or interwoven fibers comprising carbon nanotubes, a variety of conductive materials, a variety of semi-conductive materials, and/or other materials that are relatively thin, strong and electrically conductive, or combinations of the foregoing. Embodiments of the present invention provide for an electrode that comprises one or more fibers that may be capable of penetrating an outer surface of a target tissue (e.g., a nerve bundle or an individual nerve) upon which the electrode is operatively coupled. Where the target tissue is a nerve bundle, the fibers of the electrode may penetrate the outer surface of a portion of the nerve to reach an interior portion of the nerve bundle to allow an electrical signal to be applied within the nerve bundle. Such an electrode will advantageously allow for greater electrical flux into the target nerve, and may permit recruitment and/or modulation of nerve fibers not capable of modulation with prior art electrodes coupled only to an outer surface of the nerve. Embodiments of the present invention provide for a fibrous neurostimulation electrode that is capable of delivering electrical signals to an interior portion of a cranial nerve.
Utilizing embodiments of the present invention, the penetration of the fibrous material operatively coupled to the electrode into the interior portion of the nerve may be used to cause the electrical signal to penetrate into the interior portions of the tissue to a greater depth than electrodes lacking said fibrous material, e.g., to various nerve fibers (axons) within the nerve bundle. Therefore, utilizing the electrodes of embodiments of the present invention, an increased population of nerve fibers may be modulated by the electrical signal. The “fibrous” or “fiber” electrodes of the present invention provides for conductive communication with an interior portion of the nerve. The fiber or fibrous material may be of one or more of a plurality of materials, such as a stainless steel fiber, a carbon nanotube fiber, a conductive graphite fiber, a titanium fiber, a gold fiber, a copper fiber, silicon oxide, and/or one or more of any of a plurality of conductive materials capable of being formed into fibers of relatively small dimensions, e.g., below 1.0 mm.
The fibrous electrodes disclosed by embodiments of the present invention may also be used for sensing operations. Therefore, the fibers e.g., microfibers or nanofibers, that are coupled to a first electrode may provide for an increased population of nerve fibers being included and observed in sensing operations. Further, utilizing embodiments of the present invention, a decreased amount of current density may be required to modulate a larger number of nerve fibers. This may provide for usage of a lower power stimulation signal, while achieving equal or better delivery of therapeutic signals, and/or may allow therapeutic efficacy to be achieved for patients who otherwise would not respond to the electrical signal therapy.
Embodiments of the present invention provide for applying a predetermined amount of force upon the fibrous electrode, which may prompt the fibers coupled to the electrode to migrate into the nerve bundle in a relatively slow manner. In this manner, penetration of the nerve bundles may be achieved over time without substantially causing excessive trauma to the nerve or surrounding tissue. Further, a multiplexing scheme may be used to deliver current or electrical signals to various portions of a nerve in a predetermined sequence. For example, during a first time period, the electrical signal may be applied to an exterior surface of the nerve using a first surface of the electrode, while during a second time period, the electrical signal may be applied to an interior portion of the nerve using a second, fibrous portion of the electrode. In this manner, a multiplexing scheme may be used to prompt increased diversity of nerve fibers recruited by the electrical signal. Similar benefits may be obtained when the electrode is used to sense electrical activity in the nerve bundle.
Although not so limited, a system capable of implementing embodiments of the present invention is described below.
A fibrous electrode assembly 225, preferably comprising a plurality of electrodes having at least an electrode pair, is conductively connected to the distal end of the lead assembly 222, which preferably comprises a plurality of lead wires (one wire for each electrode). Each electrode in the electrode assembly 225 may operate independently or alternatively, may operate in conjunction with the other electrodes. Each electrode may comprise one or more fibrous electrodes for applying electrical signals to a nerve bundle. In some embodiments, the fibrous portions of the electrode penetrate an outer surface of the nerve bundle to deliver electrical charge to an interior of the nerve bundle. In other embodiments, the fibers do not penetrate into the interior of the nerve, but provide for a higher charge flux into the target portion of the nerve compared to prior art electrodes. Some prior art electrodes for stimulation of neural tissues have extremely small surface areas, resulting in relatively high electrical flux across that area. When the electrical flux exceeds a threshold, the molecules of the metal electrode can be dissolved into the surrounding body fluids, which is usually toxic to the neural tissue. Because the fibers coupled to the electrode significantly increase the surface area across which the electrical charge is transferred, it provides a significantly reduced risk of electrode dissolution, thereby providing increased safety where a patient is treated with relatively strong electrical signals.
Referring again to
The electrical pulse generator 210 may be programmed with an external device, such as computer 250 using programming software known in the art of implantable medical devices. A programming wand 255 may be coupled to the computer 250 as part of the external device to facilitate radio frequency (RF) communication between the computer 250 and the pulse generator 210. The programming wand 255 and computer 250 permit non-invasive communication with the generator 210 after the latter is implanted. In systems where the computer 250 uses one or more channels in the Medical Implant Communications Service (MICS) bandwidths, the programming wand 255 may be omitted to permit more convenient communication directly between the computer 250 and the pulse generator 210.
Turning now to
Referring to
Referring simultaneously to
The fibers 550 provide for an electrical path from the IMD 200, through the lead assembly 222, through the element 560, 570, and onto an inner portion of a nerve bundle 300. More specifically, the electrode assembly 500 provides a path from the fibers 550 and inner surface 540 of the cathode element 560, through the outer surface 340 of the nerve and into the inner portion 350 thereof, through the nerve tissue and into the fibers 550 and inner surface 540 of the anode element 570.
Turning now to
In one embodiment, the penetration of the fibers 550 into the nerve 300 may take place at such a rate that trauma to the nerve 300 is eliminated. In yet another alternative embodiment, migration of the fibers 550 may be controlled by electrical means (e.g., by providing predetermined electrical pulses to prompt migration of the fibers 550) such that the fibers 550 may penetrate the outer surface 340 of the nerve 300 substantially without causing excessive damage to the nerve. Other means, such as external force, small movement, etc., may be used to cause the penetration of the fibers into the neurons. In still another embodiment, fibers 550 may be formed of a shape-memory metal such as Nitinol, and coupled by known means substantially perpendicular to inner surfaces 540 of an electrode element. The fibers may then be substantially flattened against inner surface 540 by mechanical means, thereby rendering the electrode element easier and safer to couple to the nerve. The shape-memory metal may be fabricated to return to its fabrication state (i.e., substantially perpendicular to inner surface 540) at a predetermined temperature, e.g., a temperature at or slightly above or below body temperature. Thus, after the electrode assembly 500 is wrapped around the nerve 300, the temperature of the patient's body causes the fibers 550 to return to a substantially perpendicular orientation relative to inner surface 540 to facilitate penetration of the fibers 550 into inner portion 350 of the nerve 300.
In alternative embodiments substantially the entire length of the fibers 550 may be conductive, and penetration of charge into specific areas of the inner portion 350 of the nerve 300 may be controlled by the distribution and length of the fibers 550.
Utilizing embodiments of the present invention, a more robust delivery of electrical signal/stimulation may be achieved. This may increase efficacy and provide various advantages, such as increased population of nerve fibers being activated by stimulation. Further advantages provided by embodiments of the present invention may include increased population of nerve fibers being accessed for observation during sensing operations. These advantages may lead to a reduction of the power used by the IMD since more direct current electrical signals may be provided.
All of the methods and apparatuses disclosed and claimed herein may be made and executed without undue experimentation in light of the present disclosure. While the methods and apparatus of this invention have been described in terms of particular embodiments, it will be apparent to those skilled in the art that variations may be applied to the methods and apparatus and in the steps, or in the sequence of steps, of the methods described herein without departing from the concept, spirit, and scope of the invention, as defined by the appended claims. It should be especially apparent that the principles of the invention may be applied to selected cranial nerves other than, or in addition to, the vagus nerve to achieve particular results in treating patients having epilepsy. More generally, the techniques and apparatus of the present invention may be applied to any neural structure with regard to which a more controlled delivery of an electrical signal throughout the structure (as opposed to its periphery only) is desired or needed.
The particular embodiments disclosed above are illustrative only as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown other than as described in the claims below. It is, therefore, evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.
Number | Name | Date | Kind |
---|---|---|---|
3421511 | Schwartz et al. | Jan 1969 | A |
3760812 | Timm et al. | Sep 1973 | A |
3796221 | Hagfors | Mar 1974 | A |
4291699 | Geddes et al. | Sep 1981 | A |
4305402 | Katims | Dec 1981 | A |
4384926 | Wagner | May 1983 | A |
4407303 | Akerstrom | Oct 1983 | A |
4458696 | Larimore | Jul 1984 | A |
4459989 | Borkan | Jul 1984 | A |
4573481 | Bullara | Mar 1986 | A |
4590946 | Loeb | May 1986 | A |
4592359 | Galbraith | Jun 1986 | A |
4606349 | Livingston et al. | Aug 1986 | A |
4608985 | Crish et al. | Sep 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4628942 | Sweeney et al. | Dec 1986 | A |
4630615 | Yomtov | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4793353 | Borkan | Dec 1988 | A |
4821724 | Whigham et al. | Apr 1989 | A |
4827932 | Ideker et al. | May 1989 | A |
4850356 | Heath | Jul 1989 | A |
4860616 | Smith | Aug 1989 | A |
4867164 | Zabara | Sep 1989 | A |
4870341 | Pihl et al. | Sep 1989 | A |
4899750 | Ekwall | Feb 1990 | A |
4903700 | Whigham et al. | Feb 1990 | A |
4920979 | Bullara | May 1990 | A |
4964407 | Baker, Jr. et al. | Oct 1990 | A |
4969468 | Byers et al. | Nov 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
5003975 | Hafelfinger et al. | Apr 1991 | A |
5025807 | Zabara | Jun 1991 | A |
5095905 | Klepinski | Mar 1992 | A |
5111815 | Mower | May 1992 | A |
5137020 | Wayne et al. | Aug 1992 | A |
5137021 | Wayne et al. | Aug 1992 | A |
5139028 | Steinhaus et al. | Aug 1992 | A |
5146920 | Yuuchi et al. | Sep 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5201808 | Steinhaus et al. | Apr 1993 | A |
5201865 | Kuehn | Apr 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5237991 | Baker, Jr. et al. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5351394 | Weinberg | Oct 1994 | A |
5411528 | Miller et al. | May 1995 | A |
5431692 | Hansen et al. | Jul 1995 | A |
5466255 | Franchi | Nov 1995 | A |
5501702 | Plicchi et al. | Mar 1996 | A |
5507786 | Morgan et al. | Apr 1996 | A |
5522865 | Schulman et al. | Jun 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5534018 | Wahlstrand et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5549646 | Katz et al. | Aug 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5575813 | Edell et al. | Nov 1996 | A |
5620474 | Koopman | Apr 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5713936 | Staub et al. | Feb 1998 | A |
5741311 | Mc Venes et al. | Apr 1998 | A |
5743860 | Hively et al. | Apr 1998 | A |
5755742 | Schuelke et al. | May 1998 | A |
5755747 | Daly et al. | May 1998 | A |
5759199 | Snell et al. | Jun 1998 | A |
5769873 | Zadeh | Jun 1998 | A |
5796044 | Cobian et al. | Aug 1998 | A |
5814088 | Paul et al. | Sep 1998 | A |
5876425 | Gord et al. | Mar 1999 | A |
5891179 | Er et al. | Apr 1999 | A |
5897577 | Cinbis et al. | Apr 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919220 | Stieglitz et al. | Jul 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5995868 | Dorfmeister et al. | Nov 1999 | A |
6035237 | Schulman et al. | Mar 2000 | A |
6052624 | Mann | Apr 2000 | A |
6073050 | Griffith | Jun 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6154678 | Lauro | Nov 2000 | A |
6171239 | Humphrey | Jan 2001 | B1 |
6181969 | Gord | Jan 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6212431 | Hahn et al. | Apr 2001 | B1 |
6216045 | Black et al. | Apr 2001 | B1 |
6259951 | Kuzma et al. | Jul 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6317633 | Jorgenson et al. | Nov 2001 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6393325 | Mann et al. | May 2002 | B1 |
6400988 | Gurewitsch | Jun 2002 | B1 |
6418348 | Witte | Jul 2002 | B1 |
6445951 | Mouchawar | Sep 2002 | B1 |
6453198 | Torgerson et al. | Sep 2002 | B1 |
6456481 | Stevenson | Sep 2002 | B1 |
6473653 | Schallhorn et al. | Oct 2002 | B1 |
6477417 | Levine | Nov 2002 | B1 |
6490486 | Bradley | Dec 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6510332 | Greenstein | Jan 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6600957 | Gadsby | Jul 2003 | B2 |
6606523 | Jenkins | Aug 2003 | B1 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6620186 | Saphon et al. | Sep 2003 | B2 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6648823 | Thompson | Nov 2003 | B2 |
6658294 | Zadeh et al. | Dec 2003 | B1 |
6662053 | Borkan | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6687538 | Hrdlicka et al. | Feb 2004 | B1 |
6690974 | Archer et al. | Feb 2004 | B2 |
6711440 | Deal et al. | Mar 2004 | B2 |
6718203 | Weiner et al. | Apr 2004 | B2 |
6718207 | Connelly | Apr 2004 | B2 |
6721600 | Jorgenson et al. | Apr 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6725092 | MacDonald et al. | Apr 2004 | B2 |
6731979 | MacDonald | May 2004 | B2 |
6745077 | Griffith et al. | Jun 2004 | B1 |
6754539 | Erickson et al. | Jun 2004 | B1 |
6757566 | Weiner et al. | Jun 2004 | B2 |
6760624 | Anderson et al. | Jul 2004 | B2 |
6760625 | Kroll | Jul 2004 | B1 |
6760628 | Weiner et al. | Jul 2004 | B2 |
6763268 | MacDonald et al. | Jul 2004 | B2 |
6778856 | Connelly et al. | Aug 2004 | B2 |
6792316 | Sass | Sep 2004 | B2 |
6795730 | Connelly et al. | Sep 2004 | B2 |
6795736 | Connelly et al. | Sep 2004 | B2 |
6799069 | Weiner et al. | Sep 2004 | B2 |
6804557 | Kroll | Oct 2004 | B1 |
6819954 | Connelly | Nov 2004 | B2 |
6819958 | Weiner et al. | Nov 2004 | B2 |
6829509 | MacDonald et al. | Dec 2004 | B1 |
6843870 | Bluger | Jan 2005 | B1 |
6845266 | Weiner et al. | Jan 2005 | B2 |
6850805 | Connelly et al. | Feb 2005 | B2 |
6875180 | Weiner et al. | Apr 2005 | B2 |
6901290 | Foster et al. | May 2005 | B2 |
6906256 | Wang | Jun 2005 | B1 |
6907295 | Gross et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6925328 | Foster et al. | Aug 2005 | B2 |
6944489 | Zeijlemaker et al. | Sep 2005 | B2 |
6949929 | Gray et al. | Sep 2005 | B2 |
6954674 | Connelly | Oct 2005 | B2 |
6961618 | Osorio et al. | Nov 2005 | B2 |
6985775 | Reinke et al. | Jan 2006 | B2 |
6993387 | Connelly et al. | Jan 2006 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7010357 | Helfer et al. | Mar 2006 | B2 |
7013174 | Connelly et al. | Mar 2006 | B2 |
7015393 | Weiner et al. | Mar 2006 | B2 |
7047074 | Connelly et al. | May 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7107097 | Stern et al. | Sep 2006 | B2 |
7123013 | Gray | Oct 2006 | B2 |
7171166 | Ng et al. | Jan 2007 | B2 |
7174219 | Wahlstrand et al. | Feb 2007 | B2 |
7212869 | Wahlstrom | May 2007 | B2 |
7221981 | Gliner | May 2007 | B2 |
7239924 | Kolberg | Jul 2007 | B2 |
7289856 | Karicherla | Oct 2007 | B1 |
7584004 | Caparso et al. | Sep 2009 | B2 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20030083726 | Zeijlemaker et al. | May 2003 | A1 |
20030195601 | Hung et al. | Oct 2003 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040147992 | Bluger et al. | Jul 2004 | A1 |
20040167583 | Knudson et al. | Aug 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040210291 | Erickson | Oct 2004 | A1 |
20050015128 | Rezai et al. | Jan 2005 | A1 |
20050016657 | Bluger | Jan 2005 | A1 |
20050107858 | Bluger | May 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050154435 | Stern et al. | Jul 2005 | A1 |
20050222642 | Przybyszewski et al. | Oct 2005 | A1 |
20050272280 | Osypka | Dec 2005 | A1 |
20060058597 | Machado et al. | Mar 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060184211 | Gaunt et al. | Aug 2006 | A1 |
20060224199 | Zeijlemaker et al. | Oct 2006 | A1 |
20060253164 | Zhang et al. | Nov 2006 | A1 |
20060265025 | Goetz et al. | Nov 2006 | A1 |
20070027497 | Parnis et al. | Feb 2007 | A1 |
20070027498 | Maschino et al. | Feb 2007 | A1 |
20070027500 | Maschino et al. | Feb 2007 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070060991 | North et al. | Mar 2007 | A1 |
20070073150 | Gopalsami et al. | Mar 2007 | A1 |
20070100392 | Maschino et al. | May 2007 | A1 |
20070142889 | Whitehurst et al. | Jun 2007 | A1 |
20070173902 | Maschino et al. | Jul 2007 | A1 |
20070179557 | Maschino et al. | Aug 2007 | A1 |
20070179579 | Feler et al. | Aug 2007 | A1 |
20070179584 | Gliner | Aug 2007 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080046035 | Fowler et al. | Feb 2008 | A1 |
20080071323 | Lowry et al. | Mar 2008 | A1 |
20080200925 | Johnson et al. | Aug 2008 | A1 |
20080215110 | Gunderson et al. | Sep 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20090076567 | Fowler et al. | Mar 2009 | A1 |
Number | Date | Country |
---|---|---|
2004069330 | Aug 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20080183258 A1 | Jul 2008 | US |